MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1159/000541349

Медицинская библиотека · Ophthalmic research · 2024

Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.

García-Layana Alfredo, Chi Gloria C, Kodjikian Laurent, Parravano Mariacristina, Chow David, Jackson Timothy L, Danzig Carl, Paris Liliana P, Mirt Mirela, Henry-Szatkowski Mickael, Lewis Hannah B, Gentile Brittany

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options.

METHODS

This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the USA, Canada, France, Italy, Spain, and the UK. The DCE design was informed by a targeted literature review and qualitative interview research and included five treatment attributes: mode of administration, frequency of examinations, frequency of injections or refills, likely change in visual acuity, and eye-related side effects. Conditional logit models were used to analyze the choice data.

RESULTS

Overall, 537 patients completed the DCE (DME, n = 173; nAMD, n = 364). Patients reported preferring "injection" over "implant surgery and refills" and better visual outcomes over "stabilization," which were also the most important attributes driving preference (35.1% and 31.5%, respectively). They also showed a preference for less-frequent treatment and examinations and for "mild-moderate, frequent" over "severe, rare" side effects. These findings were generally consistent across the two conditions, although significant differences were found depending on anti-VEGF treatment duration (nAMD, DME) and number of reported barriers (nAMD).

CONCLUSION

Patient preferences for treatment are driven by several factors. Considering these preferences is essential when designing/introducing new therapies. Individual treatment preferences should be identified and given key consideration when helping patients select from an expanding array of treatment options.

Для цитирования: García-Layana Alfredo, Chi Gloria C, Kodjikian Laurent, Parravano Mariacristina, Chow David, Jackson Timothy L, Danzig Carl, Paris Liliana P, Mirt Mirela, Henry-Szatkowski Mickael, Lewis Hannah B, Gentile Brittany. Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.. Ophthalmic research. 2024. DOI: 10.1159/000541349.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.